Ensysce director buys 400k shares, converts notes
Ensysce Biosciences director Bob G. Gower reported net share acquisitions in Ensysce Biosciences, Inc. On 7 August 2026 he purchased 400,000 shares of common stock at $0.495 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ensysce Biosciences director Bob G. Gower reported net share acquisitions in Ensysce Biosciences, Inc. On 7 August 2026 he purchased 400,000 shares of common stock at $0.495 per share. On 23 April 2026 he purchased 508,614 shares at $0.484 per share and reported a conversion of senior convertible promissory notes into 254,307 common shares and a warrant for 254,307 shares at a conversion price of $0.484 per share. A footnote states the notes had an aggregate principal of $216,000, with outstanding principal plus accrued interest of $246,169 in April 2026, and that reported beneficial ownership reflects two reverse stock splits.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 400,000 | $0.495 | $198K |
| Conversion | Warrant F2 | 254,307 | -- | -- |
| Purchase | Common Stock F1 | 508,614 | $0.484 | $246K |
Footnotes (2)
- F1. The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person.
- F2. Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169.
Key Figures
Key Terms
reverse stock splits financial
senior convertible promissory notes financial
warrant financial
beneficially owned financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider purchases did ENSC director Bob G. Gower report in this Form 4?
What were the terms of the senior convertible promissory notes mentioned for ENSC?
What warrant position did Bob G. Gower report for Ensysce Biosciences (ENSC)?
Were Gower’s ENSC transactions reported as made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.